ResMed adds Becton Dickinson’s CFO Christopher DelOrefice to board

ResMed (RMD) announced it has expanded the size of its board of directors to 11 and has elected Christopher DelOrefice to the board, effective immediately. Mr. DelOrefice was appointed during ResMed’s regularly scheduled board meeting on August 15 and will stand for re-election with the rest of ResMed’s directors at its annual meeting on November 21 . Mr. DelOrefice has also been appointed as a member of ResMed’s board audit committee. DelOrefice currently serves as executive vice president and chief financial officer CFO of Becton, Dickinson (BDX) and Company BD and brings over 30 years of audit, finance, and strategic expertise to augment and strengthen ResMed’s diverse board. Before joining BD in September 2021, DelOrefice served in many roles at Johnson & Johnson (J&J), including most recently as vice president of investor relations and previously as CFO of J&J’s consumer and medical device business segments for North America, along with roles in finance leadership for supply chain, corporate mergers and acquisitions, consumer research and development, and business development for J&J’s North America pharmaceutical business. Before J&J, DelOrefice held positions of increasing responsibility in accounting, global audit, and financial reporting at AstraZeneca, AET Films, and Ametek.